Skip directly to content


Shortage of Injectable Estrogen a Crisis for Transgender Women

Public health experts call on FDA to better manage drug shortage process

December 5, 2016―Today, The Fenway Institute of Fenway Health, Callen-Lorde Community Health Center, and Treatment Action Group (TAG) released a policy brief documenting the public health emergency created by a shortage of injectable estrogen, and calling on the U.S. Food and Drug Administration (FDA) to be more proactive in resolving the crisis.

Injectable estrogen is a commonly prescribed hormone therapy for transgender women and comes in 40 mg/mL, 20 mg/mL, and 10mg/mL dosages.